1. Home
  2. ZLAB vs HIW Comparison

ZLAB vs HIW Comparison

Compare ZLAB & HIW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ZLAB
  • HIW
  • Stock Information
  • Founded
  • ZLAB 2013
  • HIW 1978
  • Country
  • ZLAB China
  • HIW United States
  • Employees
  • ZLAB N/A
  • HIW N/A
  • Industry
  • ZLAB Biotechnology: Pharmaceutical Preparations
  • HIW Real Estate Investment Trusts
  • Sector
  • ZLAB Health Care
  • HIW Real Estate
  • Exchange
  • ZLAB Nasdaq
  • HIW Nasdaq
  • Market Cap
  • ZLAB 3.0B
  • HIW 3.4B
  • IPO Year
  • ZLAB 2017
  • HIW 1994
  • Fundamental
  • Price
  • ZLAB $26.91
  • HIW $31.49
  • Analyst Decision
  • ZLAB Strong Buy
  • HIW Hold
  • Analyst Count
  • ZLAB 4
  • HIW 5
  • Target Price
  • ZLAB $52.50
  • HIW $31.20
  • AVG Volume (30 Days)
  • ZLAB 960.6K
  • HIW 875.8K
  • Earning Date
  • ZLAB 11-12-2024
  • HIW 02-04-2025
  • Dividend Yield
  • ZLAB N/A
  • HIW 6.41%
  • EPS Growth
  • ZLAB N/A
  • HIW 3.74
  • EPS
  • ZLAB N/A
  • HIW 1.34
  • Revenue
  • ZLAB $355,748,000.00
  • HIW $829,290,000.00
  • Revenue This Year
  • ZLAB $48.50
  • HIW N/A
  • Revenue Next Year
  • ZLAB $47.37
  • HIW $0.07
  • P/E Ratio
  • ZLAB N/A
  • HIW $23.44
  • Revenue Growth
  • ZLAB 35.01
  • HIW N/A
  • 52 Week Low
  • ZLAB $13.48
  • HIW $21.37
  • 52 Week High
  • ZLAB $36.60
  • HIW $36.78
  • Technical
  • Relative Strength Index (RSI)
  • ZLAB 45.71
  • HIW 44.41
  • Support Level
  • ZLAB $25.85
  • HIW $30.40
  • Resistance Level
  • ZLAB $29.87
  • HIW $31.69
  • Average True Range (ATR)
  • ZLAB 1.05
  • HIW 0.60
  • MACD
  • ZLAB -0.18
  • HIW 0.05
  • Stochastic Oscillator
  • ZLAB 21.98
  • HIW 42.74

About ZLAB Zai Lab Limited

Zai Lab Ltd is a biopharmaceutical company focusing on discovering or licensing, developing, and commercializing proprietary therapeutics that address areas of unmet medical need including in the fields of oncology, autoimmune and infectious diseases. The pipeline of proprietary drug candidates of the company includes ZL-2306 for treatments across multiple solid tumor types including ovarian and certain types of breast and lung cancers; ZL-2401 which is an antibiotic in a new class of tetracycline derivatives; and ZL-2301 is an oral, small molecule which targets HCC.

About HIW Highwoods Properties Inc.

Highwoods Properties Inc is a real estate investment trust engaged in the acquisition, ownership, management, and leasing of properties in urban areas throughout the Southern United States. In terms of total square footage, the vast majority of the company's real estate portfolio comprises office buildings in terms. Highwoods Properties derives nearly all of its income in the form of rental revenue from the tenants of its buildings. The majority of this revenue comes from its holdings in the urban markets of Atlanta, Raleigh, Nashville, and Tampa. These cities also account for the majority of the square footage under the company's ownership. Highwoods Properties' largest customers include the U.S. Government, financial services firms, industrial supply retailers, and healthcare companies.

Share on Social Networks: